<DOC>
	<DOCNO>NCT01264094</DOCNO>
	<brief_summary>The purpose study evaluate efficacy Change sAg Levels Chronic Hepatitis B Patients Receiving Clevudine Treatment Over Long Period .</brief_summary>
	<brief_title>A Study Evaluate Efficacy Change sAg Levels Chronic Hepatitis B Patients Receiving Clevudine Treatment Over Long Period</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Clevudine</mesh_term>
	<criteria>1 . Patient 18 year old . 2 . Patient document HBsAg positive &gt; 6 month HBV DNA positive . 3 . Patient HBeAg positive negative . 4 . Patient ALT level â‰¥ 80 IU/L 5 . Patient able give write informed consent prior study start comply study requirement . 1 . Patient currently receive antiviral , immunomodulatory , cytotoxic corticosteroid therapy . 2 . Patients previously treat interferon within previous 3 month . 3 . Patients previously treat clevudine , lamivudine , adefovir , entecavir , telbivudine investigational nucleoside HBV infection . 4 . Patient coinfected HCV , HDV HIV . 5 . Patient pregnant breastfeeding . 6 . Patient clinically relevant history abuse alcohol drug . 7 . Patient significant immunocompromised , gastrointestinal , renal , hematological , psychiatric , bronchopulmonary , biliary disease exclude asymptomatic GB stone , neurological , cardiac , oncologic ( except HCC ) allergic disease medical illness investigator 's opinion might interfere therapy . 8 . Patient creatinine clearance le 60mL/min estimate follow formula : ( 140age year ) ( body weight [ kg ] ) / ( 72 ) ( serum creatinine [ mg/dL ] ) [ Note : multiply estimate 0.85 woman ]</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
</DOC>